A signature for induced pluripotent stem cell-associated genes in colorectal cancer

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Liu, Yu Hong ^a   Li, Ying ^a   Liu, Xun Hua ^a   Sui, Hong Mei ^a   Liu, Yong Xia ^a   Xiao, Zheng Quan ^a   Zheng, Ping ^a   Chen, Lin ^a   Yao, Su ^a   Xing, Cheng ^a   Zhou, Jun ^a   Li, Jian Ming ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal cancer; Gene expression; iPS; Prognosis

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 4; PEPTIDES AND PROTEINS; PROTEIN LIN28; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR NANOG; UNCLASSIFIED DRUG; HOMEODOMAIN PROTEIN; LIN 28 PROTEIN, HUMAN; LIN-28 PROTEIN, HUMAN; MESSENGER RNA; NANOG PROTEIN, HUMAN; POU5F1 PROTEIN, HUMAN; RNA BINDING PROTEIN; TRANSCRIPTOME;

ADOLESCENT; ADULT; ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; GENE; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; INDUCED PLURIPOTENT STEM CELL ASSOCIATED GENE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; CANCER STAGING; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MORTALITY; PATHOLOGY; PLURIPOTENT STEM CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BLOTTING, WESTERN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; OCTAMER TRANSCRIPTION FACTOR-3; PLURIPOTENT STEM CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA-BINDING PROTEINS; TRANSCRIPTOME;

MLCS; MLOWN;

EID: 84880637113     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0426-2     Document Type: Article

References (30)

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-76.
2. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917-20.
3. Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, Tanaka F, et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci USA. 2010;107:40-5.
4. Saiki Y, Ishimaru S, Mimori K, Takatsuno Y, Nagahara M, Ishii H, et al. Comprehensive analysis of the clinical significance of inducing pluripotent stemness-related gene expression in colorectal cancer cells. Ann Surg Oncol. 2009;16:2638-44.
5. Rody A, Karn T, Ruckhaeberle E, Hanker L, Gaetje R, Holtrich U, et al. Differentially expressed genes of reprogrammed human pluripotent stem cells in breast cancer. Eur J Cancer. 2008;44:1789-92.
6. Kakkis E, Riggs KJ, Gillespie W, Calame K. A transcriptional repressor of c-myc. Nature. 1989;339:718-21.
7. Hagos EG, Ghaleb AM, Kumar A, Neish AS, Yang VW. Expression profiling and pathway analysis of Kruppel-like factor 4 in mouse embryonic fibroblasts. Am J Cancer Res. 2011;1:85-97.
8. Chang G, Miao YL, Zhang Y, Liu S, Kou Z, Ding J, et al. Linking incomplete reprogramming to the improved pluripotency of murine embryonal carcinoma cell-derived pluripotent stem cells. PLoS ONE. 2010;5:e10320.
9. Gazouli M, Roubelakis MG, Theodoropoulos GE, Papailiou J, Vaiopoulou A, Pappa KI, et al. OCT4 spliced variant OCT4B1 is expressed in human colorectal cancer. Mol Carcinog. 2012;51:165-73.
10. Meng HM, Zheng P, Wang XY, Liu C, Sui HM, Wu SJ, et al. Overexpression of nanog predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol Ther. 2010;9:295-302.
11. Fang X, Yu W, Li L, Shao J, Zhao N, Chen Q, et al. ChIP-seq and functional analysis of the SOX2 gene in colorectal cancers. OMICS. 2010;14:369-84.
12. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, et al. Metastasis-associated gene expression changes predict poor outcomes in patients with dukes Stage B and C colorectal cancer. Clin Cancer Res. 2009;15:7642-51.
13. Papp B, Plath K. Reprogramming to pluripotency: stepwise resetting of the epigenetic landscape. Cell Res. 2011;21:486-501.
14. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-72.
15. Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene. 2012;31:1354-65.
16. Jeter CR, Liu B, Liu X, Chen X, Liu C, Calhoun-Davis T, et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene. 2011;30:3833-45.
17. Chiou SH, Wang ML, Chou YT, Chen CJ, Hong CF, Hsieh WJ, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res. 2010;70:10433-44.
18. Brandner S. Nanog, Gli, and p53: a new network of stemness in development and cancer. EMBO J. 2010;29:2475-6.
19. Po A, Ferretti E, Miele E, De Smaele E, Paganelli A, Canettieri G, et al. Hedgehog controls neural stem cells through p53-independent regulation of Nanog. EMBO J. 2010;29:2646-58.
20. Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene. 2010;29:2153-9.
21. Hubbard SA, Friel AM, Kumar B, Zhang L, Rueda BR, Gargett CE. Evidence for cancer stem cells in human endometrial carcinoma. Cancer Res. 2009;69:8241-8.
22. Utikal J, Maherali N, Kulalert W, Hochedlinger K. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci. 2009;122:3502-10.
23. Stoop H, Honecker F, van de Geijn GJ, Gillis AJ, Cools MC, de Boer M, et al. Stem cell factor as a novel diagnostic marker for early malignant germ cells. J Pathol. 2008;216:43-54.
24. Glinsky GV. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol. 2008;26:2846-53.
25. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008;40:499-507.
26. Guo Y, Mantel C, Hromas RA, Broxmeyer HE. Oct-4 is critical for survival/antiapoptosis of murine embryonic stem cells subjected to stress: effects associated with Stat3/survivin. Stem Cells. 2008;26:30-4.
27. Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 2009;16:3488-98.
28. Merlos-Suarez A, Barriga FM, Jung P, Iglesias M, Cespedes MV, Rossell D, et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell. 2011;8:511-24.
29. Yan X, Ma L, Yi D, Yoon JG, Diercks A, Foltz G, et al. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci USA. 2011;108:1591-6.
30. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005;115:1503-21.